4D Molecular Therapeutics (FDMT) Operating Income (2020 - 2026)

4D Molecular Therapeutics (FDMT) has 7 years of Operating Income data on file, last reported at -$73.6 million in Q1 2026.

• On a quarterly basis, Operating Income fell 37.3% year-over-year to -$73.6 million in Q1 2026; TTM through Mar 2026 was -$179.5 million, a 11.7% increase from a year earlier, with the FY2025 full-year figure at -$159.5 million, up 15.06% from the prior year.
• Operating Income for Q1 2026 stood at -$73.6 million, down from $14.7 million in the prior quarter.
• Over the last five years, Operating Income for FDMT reached as high as $14.7 million in Q4 2025 and fell as low as -$73.6 million in Q1 2026.
• Historically, Operating Income has averaged -$37.9 million across 5 years, with a median of -$36.7 million in 2023.
• Across the five-year window, Operating Income tumbled 274.22% in 2022 and soared 126.22% in 2025, its largest moves.
• Year by year, Operating Income stood at -$28.7 million in 2022, then retreated by 27.62% to -$36.7 million in 2023, then tumbled by 53.11% to -$56.1 million in 2024, then surged by 126.22% to $14.7 million in 2025, then plunged by 600.31% to -$73.6 million in 2026.
• Per Business Quant data, the three most recent Operating Income figures were -$73.6 million in Q1 2026, $14.7 million in Q4 2025, and -$61.2 million in Q3 2025.